Use of effect size to determine optimal dose of duloxetine in major depressive disorder

Journal of Psychiatric Research

Volumn 41, Issue 3-4, 2007, Pages 311-318

  Pritchett, Yili L ^a   Marciniak, Martin D ^a   Corey Lisle, Patricia K ^b   Berzon, Richard A ^c   Desaiah, Durisala ^a   Detke, Michael J ^a,d,e  

^a ELI LILLY AND COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dose response; Duloxetine; Effect size; MDD; Optimal dose

Indexed keywords

DULOXETINE; PAROXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REMISSION; XEROSTOMIA;

EID: 33845227124     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2006.06.013     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: 1994.
2. Bech P. Measurement issues. In: D'Haenen H., et al. (Ed). Textbook of biological psychiatry. Part 1: Basic principles (2002), Wiley, New York 25-36
3. Bech P., Tanghoj P., Andersen H.F., et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology 163 (2002) 20-25
4. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialog in Clinical Neuroscience 7 (2005) 249-262
5. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clinical Pharmacology Therapeutics 66 (1999) 152-165
6. Detke M.J., Lu Y., Goldstein D.J., et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry 63 (2002) 308-315
7. Detke M.J., Lu Y., Goldstein D.J., et al. Duloxetine, 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research 36 (2002) 383-390
8. Detke M.J., Wiltse C.G., Mallincrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 14 (2004) 457-470
9. Dunner D.L., Wohlreich M.M., Mallinckrodt C., Watkin J.G., and Fava M. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Current Therapeutic Research 66 6 (2005) 1-19
10. Fabre L.F., Abuzzahab F.S., Amin M., Claghorn J.L., Mendels J., Petrie W.M., et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biological Psychiatry 38 (1995) 592-602
11. Faries D., Herrera J., Rayamajhi J., DeBrota D., Demitrack M., and Potter W.Z. The responsiveness of the Hamilton Depression Rating Scale. Journal of Psychiatric Research 34 (2000) 3-10
12. Feighner J.P., and Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Journal of Clinical Psychiatry 60 (1999) 824-830
13. Gleser L.J., and Olkin I. In: Stangl D.K., and Berry D.A. (Eds). Meta-analysis for 2*2 tables with multiple treatment groups in meta-analysis in medicine and health policy (2000), Marcel Dekker, Inc., New York, NY
14. Goldstein D.J., Mallincrodt C.H., Lu Y., et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Journal of Clinical Psychiatry 63 (2002) 225-231
15. Goldstein D.J., Lu Y., Detke M.J., et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 24 (2004) 389-399
16. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23 (1960) 56-62
17. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social Clinical Psychiatry 6 (1967) 278-296
18. Hedges L.V., and Olkin I. Statistical methods for meta-analysis (1985), Academic Press, Inc., Orlando
19. Khan A., Khan S.R., Walens G., Kolts R., and Giller E.L. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28 (2003) 552-557
20. Mendels J., Kiev A., and Fabre L.F. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depression and Anxiety 9 (1999) 54-60
21. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin 36 (2002) 106-132
22. Perahia D.G., Gilaberte I., Wang F., Wiltze C.G., Huckins S.A., Clemens J.W., et al. Duloxetine in the prevention of relapse of major depressive disorder: a double-blind, placebo-controlled study. British Journal of Psychiatry 188 4 (2006)
23. Sharma A., Goldberg M.J., and Cerimele B.J. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. Journal of Clinical Pharmacology 40 (2000) 161-167
24. Simpson G.M., Lee J.H., Cuculic Z., and Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Archives of General Psychiatry 33 (1976) 1093-1102
25. Tran P, Lu Y, Martynov O, Detke, M. Safety and tolerability of duloxetine versus paroxetine. In: Poster presented at the American Psychiatric Association 2003, San Francisco, CA, 17-22 May.
26. Wernicke J.F., Dunlop S.R., Dornseif B.E., and Zerbe R.L. Fixed dose fluoxetine therapy for depression. Psychopharmacology Bulletin 23 (1987) 164-168
27. Westanmo A.D., Gayken J., and Haight R. Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor. American Journal of Health-System Pharmacy 62 (2005) 2481-2490